CTOs on the Move

Cambrian Innovation

www.cambrianinnovation.com

 
Spun out of MIT in 2006, Cambrian Innovation is commercializing a portfolio of environmental solutions based on newly discovered electrically active microbes. By harnessing the power of bio-electricity and advances in electrochemistry, Cambrian Innovation`s products help industrial, agricultural, and government customers save money while recovering clean water and clean energy from wastewater streams. Our bio-electrogenic sensor platform enables low-cost, real-time monitoring of critical natural resources. At Cambrian Innovation our vision is simple: Industry is an ecosystem. Because the biological world is by definition sustainable, creative application of biological engineering is the best way to solve our most pressing environmental challenges. ...
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Cambrian Innovation raised $18M on 10/30/2019

Similar Companies

Quadrant Laboratories

Quadrant Laboratories is a subsidiary of Quadrant Biosciences, a life sciences company focused on improving the lives of children and families through innovative diagnostic, therapeutic, and virtual care solutions for global health priorities. Quadrant...

Cadence Human Systems

Cadence Human Systems is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relay Technology Management

Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.

Teva parenteral Medicines

Teva parenteral Medicines is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Translate Bio

Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Our proprietary mRNA therapeutic platform (MRTTM) is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. We believe that our MRTTM platform is applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease, including diseases that affect the lung, liver, eye, central nervous system, lymphatic system and circulatory system. Our two lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency.